Technical Analysis for CNTB - Connect Biopharma Holdings Limited

Grade Last Price % Change Price Change
C 1.24 -4.62% -0.06
CNTB closed down 4.62 percent on Monday, March 18, 2024, on 73 percent of normal volume. It was able to find support at its 50 day moving average.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
50 DMA Support Bullish 0.00%
Crossed Above 20 DMA Bullish -4.62%
Crossed Above 50 DMA Bullish -4.62%
180 Bullish Setup Bullish Swing Setup -4.62%
Expansion Pivot Buy Setup Bullish Swing Setup -4.62%
Pocket Pivot Bullish Swing Setup -4.62%
20 DMA Resistance Bearish 10.71%
Fell Below 50 DMA Bearish 10.71%
Expansion Pivot Sell Setup Bearish Swing Setup 10.71%

   Recent Intraday Alerts

Alert Time
20 DMA Support about 10 hours ago
1.5x Volume Pace about 10 hours ago
50 DMA Support about 11 hours ago
60 Minute Opening Range Breakdown about 11 hours ago
Down 5% about 11 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Connect Biopharma Holdings Limited Description

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Immunology Immune System Immunotherapy Inflammation Asthma Atopic Dermatitis Chronic Rhinosinusitis Human Physiology Skin Inflammation Animal Physiology Interleukins Nasal Polyps

Is CNTB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.84
52 Week Low 0.5347
Average Volume 128,520
200-Day Moving Average 1.10
50-Day Moving Average 1.19
20-Day Moving Average 1.22
10-Day Moving Average 1.24
Average True Range 0.15
RSI (14) 51.22
ADX 18.66
+DI 15.66
-DI 13.16
Chandelier Exit (Long, 3 ATRs) 0.99
Chandelier Exit (Short, 3 ATRs) 1.42
Upper Bollinger Bands 1.37
Lower Bollinger Band 1.07
Percent B (%b) 0.57
BandWidth 24.35
MACD Line 0.01
MACD Signal Line 0.02
MACD Histogram -0.0037
Fundamentals Value
Market Cap 68.29 Million
Num Shares 55.1 Million
EPS -1.56
Price-to-Earnings (P/E) Ratio -0.79
Price-to-Sales 0.00
Price-to-Book 0.47
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.48
Resistance 3 (R3) 1.48 1.40 1.44
Resistance 2 (R2) 1.40 1.34 1.40 1.43
Resistance 1 (R1) 1.32 1.30 1.28 1.32 1.41
Pivot Point 1.24 1.24 1.22 1.24 1.24
Support 1 (S1) 1.16 1.18 1.12 1.16 1.07
Support 2 (S2) 1.08 1.14 1.08 1.05
Support 3 (S3) 1.00 1.08 1.04
Support 4 (S4) 1.00